Home

NHS could recoup cost of ineffective drugs

2007-06-04T00:00:00

The National Institute for Health and Clinical Excellence is recommending an innovative deal for an anti-cancer drug. It says patients with multiple myeloma who show a full or partial response to the drug Velcade should be kept on it and be funded by the NHS.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
  • 10 expert briefings every fortnight (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here